Pharmaceutical Executive December 12, 2024
Mike Hollan

The industry is facing an uncertain regulatory landscape in the coming year.

The recent election of Donald Trump as president of the United States is sure to have a significant impact on many industries, including the pharmaceutical and life sciences industries. Whether its actions that will have a direct impact, such as naming Robert F. Kennedy Jr to be head of the Department of Health and Human Services, or indirect impacts, such as his plans to place tariffs on certain goods, the industry is preparing for an uncertain regulatory landscape. Arthur Wong, health care managing director at S&P Global Rankings, spoke with Pharmaceutical Executive about the potential impacts of the election.

Pharmaceutical Executive: How will the expiration of ACA subsidies...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Congress / White House, Govt Agencies, Interview / Q&A, Pharma, Pharma / Biotech, Trends
Related Articles:
Mark Cuban: A Master Disrupter for American Healthcare
Despite Trump’s Tough Talk On PBMs, GOP House Lets Them Off The Hook
How has U.S. Spending on Health Care Changed Over Time?
Bringing genomics closer to patients: 3 takeaways from Henry Ford Health
Merck enters $2B licensing deal for weight loss drug

Share This Article